RecruitingPhase 1NCT06233110

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Studying Chronic graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stefanie Sarantopoulos, MD, PhD.
Principal Investigator
Chenyu Lin, MD
Duke Health
Intervention
Fostamatinib(drug)
Enrollment
30 enrolled
Eligibility
18-80 years · All sexes
Timeline
20252029

Study locations (1)

Collaborators

Incyte Corporation · Rigel Pharmaceuticals · National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06233110 on ClinicalTrials.gov

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Chronic graft versus host disease

← Back to all trials